Published: July 2020
Reduced manufacturing costs, availability of cheap and skilled labor, coupled to a supportive regulatory landscape has compelled various drug developers across the globe to outsource their pharmaceutical manufacturing operations to China
Roots Analysis has announced the addition of “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report to its list of offerings.
A growing economy, large population base, and innovation-friendly environment are other key parameters that are anticipated to drive the growth of the pharmaceutical contract manufacturing market in China. Further, in order to meet the growing demand for their services, CMOs having manufacturing facilities in China are actively expanding their existing capacities and capabilities in the region.
To order this 200+ page report, which features 85+ figures and 100+ tables, please visit this link
Over 100 CMOs claim to have established their pharmaceutical manufacturing facilities in China
Presently, the contract services market in China dominated by the presence of large and very large CMOs, which represent ~70% of stakeholders in this industry. Further, it is worth highlighting that 89% CMOs having facilities in China provide services for the production of pharmaceutical APIs.
~73% of the pharmaceutical manufacturing facilities are based in Eastern China
Key manufacturing hubs within Eastern China (in terms of number of manufacturing facilities) include (in decreasing number of manufacturing facilities) Jiangsu, Zhejiang, Shanghai and Shandong. Apart from this, CMOs have also established their pharmaceutical manufacturing facilities in some emerging regions of Southern China and Northern China.
Around 90% of the total, installed pharmaceutical API contract manufacturing capacity belongs to large / very large firms
The current, installed pharmaceutical API contract manufacturing capacity in China is estimated to be around 46 million L. Further, it is worth noting that 73% of the overall production capacity is contributed by facilities based in Eastern China. As mentioned earlier, this can be attributed to the larger number of facilities established in the aforementioned region.
Several big pharma players have invested in pharmaceutical manufacturing initiatives in China
Close to half of the aforementioned initiatives were observed to be related to the establishment / expansion of pharmaceutical manufacturing facilities in China. Further, it is worth highlighting that, around 50% of the big pharma initiatives were reported to be initiated post 2010.
By 2030, API segment is anticipated to capture 66% share (in terms of service revenue) of the pharmaceutical contract manufacturing market in China
In 2020, the outsourced component of the pharmaceutical manufacturing services market in China is estimated to be worth USD 5.5 billion. Further, majority share of contract service revenues is estimated to be generated from commercial scale operations, and this trend is unlikely to change in the foreseen future as well.
To request a sample copy / brochure of this report, please visit this link
The USD 13 billion (by 2030) financial opportunity within the pharmaceuticals contract manufacturing market in China has been analyzed across the following segments:
The research covers brief profiles of several key players (including those listed below); each profile features an overview of the company, its financial information (if available), pharmaceutical manufacturing services portfolio in China, recent developments, and an informed future outlook.
For additional details, please visit
or email firstname.lastname@example.org
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry